Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 47Gynecologic 41Lymphoid 23Plasma cell 16Sarcoma 8Genitourinary 6Other hematologic neoplasm 5Gastrointestinal 5Thoracic 4Other solid neoplasm 2CNS 2Tumor-Agnostic 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Pancreatic Neoplasms 2Liver Neoplasms 2Stomach Neoplasms 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × liposomal doxorubicin × Gastrointestinal × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01464593 2022-10-13

ABLATE

Imunon

Phase 2 Terminated
2 enrolled 5 charts
Gastrointestinal

Colonic Neoplasms, Liver Neoplasms

NCT00426127 2017-12-29

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

University of Iowa

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01281943 2013-07-04

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡